Amgen Submits Biologics License Application To The FDA For Erenumab
Erenumab is an Investigative Treatment Specifically Designed to Prevent Migraine
Only Molecule in Late-Stage Development to Directly Target the Calcitonin Gene-Related Peptide Receptor
Amgen and Novartis to Co-Commercialize Erenumab in the U.S.
TH... Biopharmaceuticals, Neurology, FDA Amgen, erenumab, migraine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news